JGC
ACOR

J. Goldman & Co’s Acorda Therapeutics ACOR Stock Holding History

J. Goldman & Co’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-978
Closed -$5.02M – 375
2015
Q4 		$5.02M Sell
978
-2,040
-68% -$8.92M 0.52% 71
2015
Q3 		$9.6M Buy
+3,018
New +$11.7M 0.82% 27
2014
Q3 		– Sell
-208
Closed -$843K – 352
2014
Q2 		$843K Sell
208
-995
-83% -$4.06M 0.06% 192
2014
Q1 		$5.47M Buy
+1,203
New +$4.86M 0.4% 78

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

J. Goldman & Co's ACOR Position: Q1 2016 in Review

J. Goldman & Co sold out of Acorda Therapeutics (ACOR) in Q1 2016, closing a stake of 978 shares — an estimated $5.02M sold.

J. Goldman & Co first reported a position in ACOR in Q1 2014 and held it in 4 quarters. The position peaked at $9.6M in Q3 2015. 194 funds tracked by Wall St. Rank hold ACOR as of Q1 2016.

  • J. Goldman & Co reported no remaining Acorda Therapeutics position as of Q1 2016 after selling out during the quarter.
  • J. Goldman & Co sold 978 Acorda Therapeutics shares in Q1 2016, an estimated $5.02M.
  • J. Goldman & Co first reported a position in Acorda Therapeutics in Q1 2014 and held it in 4 quarters.
  • J. Goldman & Co's Acorda Therapeutics position peaked at $9.6M in Q3 2015.
  • 194 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2016.

Based on J. Goldman & Co's 13F filing for Q1 2016, filed 16 May 2016.